Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs.

Boesch AW, Miles AR, Chan YN, Osei-Owusu NY, Ackerman ME.

MAbs. 2017 Apr;9(3):455-465. doi: 10.1080/19420862.2016.1274845. Epub 2017 Jan 5.

2.

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.

Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR.

Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17.

PMID:
23872058
3.

Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.

Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K.

Mol Immunol. 2014 Mar;58(1):132-8. doi: 10.1016/j.molimm.2013.11.017. Epub 2013 Dec 14.

4.

Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.

Dashivets T, Thomann M, Rueger P, Knaupp A, Buchner J, Schlothauer T.

PLoS One. 2015 Dec 11;10(12):e0143520. doi: 10.1371/journal.pone.0143520. eCollection 2015.

5.

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.

Liu Z, Gunasekaran K, Wang W, Razinkov V, Sekirov L, Leng E, Sweet H, Foltz I, Howard M, Rousseau AM, Kozlosky C, Fanslow W, Yan W.

J Biol Chem. 2014 Feb 7;289(6):3571-90. doi: 10.1074/jbc.M113.513366. Epub 2013 Dec 5.

6.

Cynomolgus and pigtail macaque IgG subclasses: characterization of IGHG genes and computational analysis of IgG/Fc receptor binding affinity.

Nguyen DC, Sanghvi R, Scinicariello F, Pulit-Penaloza J, Hill N, Attanasio R.

Immunogenetics. 2014 Jun;66(6):361-77. doi: 10.1007/s00251-014-0775-4. Epub 2014 May 9.

PMID:
24811270
7.

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors.

Loyau J, Malinge P, Daubeuf B, Shang L, Elson G, Kosco-Vilbois M, Fischer N, Rousseau F.

MAbs. 2014;6(6):1621-30. doi: 10.4161/19420862.2014.975098.

8.

Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.

Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, Koeleman CAM, Wuhrer M, van den Berg TK, Rispens T, Vidarsson G, Kuijpers TW.

J Immunol. 2017 Jul 1;199(1):204-211. doi: 10.4049/jimmunol.1700116. Epub 2017 May 31.

9.

Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.

Caaveiro JM, Kiyoshi M, Tsumoto K.

Immunol Rev. 2015 Nov;268(1):201-21. doi: 10.1111/imr.12365. Review.

PMID:
26497522
10.

Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.

Ortiz DF, Lansing JC, Rutitzky L, Kurtagic E, Prod'homme T, Choudhury A, Washburn N, Bhatnagar N, Beneduce C, Holte K, Prenovitz R, Child M, Killough J, Tyler S, Brown J, Nguyen S, Schwab I, Hains M, Meccariello R, Markowitz L, Wang J, Zouaoui R, Simpson A, Schultes B, Capila I, Ling L, Nimmerjahn F, Manning AM, Bosques CJ.

Sci Transl Med. 2016 Nov 16;8(365):365ra158.

PMID:
27856797
11.

IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.

Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, Lux A, Marshall N, Lindorfer MA, Goff OR, Balbino B, Kang TH, Tanno H, Delidakis G, Alford C, Taylor RP, Nimmerjahn F, Varadarajan N, Bruhns P, Zhang YJ, Georgiou G.

Nat Immunol. 2017 Aug;18(8):889-898. doi: 10.1038/ni.3770. Epub 2017 Jun 12. Erratum in: Nat Immunol. 2017 Sep 19;18(10 ):1173.

12.

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.

Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E.

Protein Eng Des Sel. 2016 Oct;29(10):457-466. doi: 10.1093/protein/gzw040. Epub 2016 Aug 29.

PMID:
27578889
13.

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.

Mimoto F, Igawa T, Kuramochi T, Katada H, Kadono S, Kamikawa T, Shida-Kawazoe M, Hattori K.

MAbs. 2013 Mar-Apr;5(2):229-36. doi: 10.4161/mabs.23452. Epub 2013 Feb 13.

14.

Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity.

Yu X, Menard M, Prechl J, Bhakta V, Sheffield WP, Lazarus AH.

Blood. 2016 Jan 7;127(1):132-8. doi: 10.1182/blood-2015-08-664656. Epub 2015 Oct 23.

15.

Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.

Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P.

MAbs. 2015;7(4):743-51. doi: 10.1080/19420862.2015.1047570.

16.

Anti-retroviral antibody FcγR-mediated effector functions.

Bournazos S, Ravetch JV.

Immunol Rev. 2017 Jan;275(1):285-295. doi: 10.1111/imr.12482. Review.

PMID:
28133801
17.

Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages.

Nagelkerke SQ, Dekkers G, Kustiawan I, van de Bovenkamp FS, Geissler J, Plomp R, Wuhrer M, Vidarsson G, Rispens T, van den Berg TK, Kuijpers TW.

Blood. 2014 Dec 11;124(25):3709-18. doi: 10.1182/blood-2014-05-576835. Epub 2014 Oct 28.

18.

Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity.

Bournazos S, Chow SK, Abboud N, Casadevall A, Ravetch JV.

J Clin Invest. 2014 Feb;124(2):725-9. doi: 10.1172/JCI72676. Epub 2014 Jan 9.

19.

IgG Binding Characteristics of Rhesus Macaque FcγR.

Chan YN, Boesch AW, Osei-Owusu NY, Emileh A, Crowley AR, Cocklin SL, Finstad SL, Linde CH, Howell RA, Zentner I, Cocklin S, Miles AR, Eckman JW, Alter G, Schmitz JE, Ackerman ME.

J Immunol. 2016 Oct 1;197(7):2936-47. doi: 10.4049/jimmunol.1502252. Epub 2016 Aug 24.

20.

Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.

Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T, Barouch DH, Bailey-Kellogg C, Alter G, Ackerman ME.

J Immunol Methods. 2017 Apr;443:33-44. doi: 10.1016/j.jim.2017.01.010. Epub 2017 Feb 3.

Supplemental Content

Support Center